Ciprofloxacin, commonly referred to as Cipro, is a broad-spectrum antibiotic belonging to the fluoroquinolone class. Its antibacterial action is based on inhibition of bacterial DNA gyrase and topoisomerase IV, critical enzymes for bacterial DNA replication, transcription, repair and recombination. By blocking these enzymes, ciprofloxacin induces rapid bactericidal effects against both gram-negative and certain gram-positive organisms. The drug is effective against a wide array of pathogens, including Escherichia coli, Pseudomonas aeruginosa, Proteus spp., Neisseria gonorrhoeae, Haemophilus influenzae and many urinary and respiratory pathogens. Ciprofloxacin’s mechanism of action makes it particularly valuable in complicated urinary tract infections, some respiratory infections, prostatitis and certain gastrointestinal infections. Unlike bacteriostatic agents, ciprofloxacin kills the bacteria directly, reducing the bacterial load and enhancing clinical outcomes when the drug is used appropriately according to sensitivity patterns.
Pharmacologically, ciprofloxacin’s efficacy arises from concentration-dependent killing and a pronounced post-antibiotic effect, meaning bacterial growth remains suppressed even after plasma levels fall below the minimum inhibitory concentration (MIC). This supports once- or twice-daily dosing regimens, depending on the severity and type of infection. The drug’s robust tissue penetration extends to genitourinary tissues, respiratory mucosa, bone and some intracellular compartments, though cerebrospinal fluid penetration is limited. The chemical structure of ciprofloxacin includes a fluorine atom at position 6 and a cyclopropyl group at position 1, modifications that enhance potency, spectrum of activity and pharmacokinetics when compared to older quinolones.
Resistance to ciprofloxacin can develop via mutations in the genes encoding DNA gyrase or topoisomerase IV, increased drug efflux, or reduced uptake through porin channels in the bacterial cell wall. Careful use and adherence to local prescribing guidelines are therefore critical to preserve the clinical value of this antibiotic. In hospital settings, ciprofloxacin is often reserved for infections caused by multidrug-resistant organisms or when other first-line treatments are contraindicated or not tolerated.
In the United Kingdom, ciprofloxacin is classified as a Prescription Only Medicine (POM) and cannot legally be supplied without a valid prescription from a registered healthcare professional. The classification reflects the need for professional assessment, appropriate laboratory testing for susceptibility, monitoring for adverse effects and consideration of antibiotic resistance. Any claim to “buy Cipro without prescription” is inconsistent with UK regulations and may pose significant health risks. Markeaton Pharmacy complies with MHRA guidance and requires a current prescription or a pharmacy-issued clinical assessment under a Patient Group Direction (PGD) for specified indications before dispensing ciprofloxacin.
For patients requiring ongoing antibiotic therapy, remote prescription services or repeat prescribing may be arranged through an accredited online consultation with a qualified healthcare provider. After a clinical evaluation, a prescription may be issued electronically and dispensed by Markeaton Pharmacy for home delivery or collection. This process ensures that ciprofloxacin is used safely, only when indicated, and under professional supervision, thereby minimizing the risk of inappropriate use and antimicrobial resistance.
Ciprofloxacin is a first-line option for many complicated UTIs, especially those involving multidrug-resistant gram-negative organisms. The drug achieves high concentrations in urine and renal tissue, making it effective for pyelonephritis and prostatitis.
In hospital-acquired pneumonia, ventilator-associated pneumonia and some cases of community-acquired pneumonia, ciprofloxacin may be used when susceptibility is established or if first-line antibiotics are not suitable. It covers H. influenzae and atypical pathogens to a moderate extent.
Treating infectious diarrhoea due to Campylobacter, Salmonella, Shigella and enterotoxigenic E. coli in adults may involve ciprofloxacin when local resistance patterns permit.
Neisseria gonorrhoeae was once routinely treated with ciprofloxacin; however, widespread resistance has limited its use. Contemporary guidelines recommend other agents, but in selected cases with proven sensitivity, ciprofloxacin remains an option.
Its excellent bone penetration allows ciprofloxacin to be combined with other agents in osteomyelitis and septic arthritis, particularly when caused by susceptible gram-negative bacilli.
Ciprofloxacin is available in multiple oral strengths, intravenous formulations and eye/ear preparations. Oral tablets commonly come in 250 mg, 500 mg and 750 mg strengths. Extended-release tablets are typically 500 mg or 1000 mg. The appropriate dose depends on the type and severity of infection, patient renal function and clinical response.
Immediate-release tablets (250 mg, 500 mg, 750 mg) are taken twice daily. Extended-release tablets (500 mg, 1000 mg) may allow once-daily dosing for certain indications but should not be split or crushed.
Aqueous suspension (Cipro® suspension) is used for patients unable to swallow tablets. Each 5 mL contains 500 mg of ciprofloxacin base and must be shaken well before use.
IV infusion is indicated for severe infections or when oral therapy is not possible. Standard doses range from 400 mg every 8–12 hours to 400 mg twice daily, depending on indication and renal function.
Ciprofloxacin eye drops and ear drops are used for bacterial conjunctivitis, keratitis and otitis externa when directed by a clinician.
| Formulation | Strength | Typical Dosing | Administration |
|---|---|---|---|
| Immediate-release tablet | 250 mg | 250 mg every 12 hrs | Oral |
| Immediate-release tablet | 500 mg | 500 mg every 12 hrs | Oral |
| Extended-release tablet | 500 mg | 500 mg once daily | Oral |
| Oral suspension | 500 mg/5 mL | 750 mg to 1500 mg daily | Oral, shaken |
Patients with a valid prescription can purchase generic Ciprofloxacin online from Markeaton Pharmacy. Ordering is simple: upload your prescription via our secure portal, select the desired formulation, and complete payment. We offer fast UK delivery or in-store collection at 126 Kedleston Road, Derby. Prices vary by strength, pack size and brand. Generic products are significantly cheaper than brand-name equivalents.
We procure ciprofloxacin from reputable manufacturers, allowing us to offer competitive pricing. While specific lowPrice and highPrice values depend on market conditions, customers typically see savings of up to 70% compared to branded Cipro®. Price ranges for a 10-day course are shown below:
| Product | Strength | Pack size | Approx. Price (GBP) | Notes |
|---|---|---|---|---|
| Generic Ciprofloxacin | 500 mg | 20 tablets | £15–£25 | Best seller, generic |
| Branded Cipro® | 500 mg | 20 tablets | £50–£65 | Premium branded |
| Generic XR Ciprofloxacin | 1000 mg | 10 tablets | £30–£45 | Extended-release |
For current availability and exact pricing, please contact Markeaton Pharmacy at +44 1332 344049 or visit our website. Online ordering includes options for express delivery, standard shipping and same-day collection if ordered before 3 pm on weekdays.
Generic ciprofloxacin contains the same active ingredient and must meet the same quality, safety and efficacy standards as brand-name Cipro®. Differences lie in excipients, coating, tablet appearance and manufacturer. Generics offer cost savings of 50%–70% and are interchangeable when authorised by the MHRA. Patients should follow dispensing labels and healthcare advice, as formulations may have different dissolution profiles.
Ciprofloxacin is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1–2 hours. Food delays absorption but does not significantly reduce total bioavailability; however, avoid administering with dairy products or calcium-rich foods within 2 hours as they can chelate the drug and reduce absorption. Bioavailability is approximately 70%–80%. The volume of distribution is about 2–3 L/kg, indicating extensive tissue penetration.
Elimination occurs primarily via renal excretion of unchanged drug and metabolites; dosage adjustment is required in patients with creatinine clearance below 50 mL/min. The elimination half-life ranges from 4 to 6 hours in healthy adults but may be prolonged in renal impairment. Hepatic metabolism via CYP1A2 is minor. Ciprofloxacin is not significantly removed by haemodialysis or peritoneal dialysis.
Common adverse reactions include gastrointestinal symptoms such as nausea, diarrhoea, abdominal discomfort and dyspepsia. Central nervous system effects like headache, dizziness and insomnia may occur. Most side effects are mild to moderate and reversible upon discontinuation.
| System | Possible effects |
| Gastrointestinal | Nausea, vomiting, diarrhoea, abdominal pain |
| Nervous system | Headache, dizziness, tremor |
| Skin | Rash, pruritus, photosensitivity reactions |
| Musculoskeletal | Tendinitis, tendon rupture (rare but serious) |
| Hypersensitivity | Anaphylaxis, angioedema (rare) |
Patients should be advised to discontinue therapy and seek medical attention if they develop tendon pain, inflammation or rupture, severe hypersensitivity signs or psychiatric symptoms such as hallucinations or confusion. Prolonged QT interval is a rare but serious risk; use with caution in patients on other QT-prolonging agents.
Overuse and misuse of fluoroquinolones have contributed to rising resistance rates among E. coli, P. aeruginosa and other pathogens. Resistance mechanisms include target site mutations, efflux pumps and reduced permeability. To minimise resistance development:
Pregnancy and breastfeeding: Ciprofloxacin crosses the placenta and is excreted in breast milk. Use only if benefit outweighs potential risk; alternatives are preferred for uncomplicated infections in pregnancy. Paediatric use: not recommended in children except for specific indications (e.g., Pseudomonas infections in cystic fibrosis) due to effects on cartilage observed in animal studies.
Elderly: Increased risk of tendon disorders and CNS effects; start at lower end of dosing range and monitor closely. Renal impairment: adjust dose based on creatinine clearance; extended-release formulations are not recommended if CrCl <30 mL/min.
For best outcomes:
Off-label applications of ciprofloxacin may include prophylaxis for anthrax exposure, treatment of certain resistant typhoid fevers and adjunctive therapy in bone infections. Any off-label use should be guided by specialist advice and local guidelines.
Ciprofloxacin is classified as a Prescription Only Medicine (POM). It must be prescribed by a qualified healthcare professional after appropriate assessment. It cannot be sold as a general sales list (GSL) or pharmacy (P) medicine. Markeaton Pharmacy requires a valid prescription or PGD to dispense ciprofloxacin.
No. Under UK law, ciprofloxacin is POM. Claims of “no-prescription” supply are non-compliant with regulations and unsafe.
Patients often notice improvement within 48–72 hours for sensitive infections. Always complete the full course.
Take as soon as remembered unless the next dose is due soon. Do not double up on doses.
Yes, but avoid dairy or calcium-rich meals within 2 hours of dosing to ensure optimal absorption.
Avoid excessive sun exposure; ciprofloxacin may cause photosensitivity. Use adequate sun protection.